Zoetis UK Ltd announced that Simparica Trio is now licensed for the treatment of Angiostrongylus vasorum in dogs. It makes Simparica Trio the only oral moxidectin that is licensed to treat A.vasorum in dogs in the UK.
“The last time a product was licensed for the treatment of lungworm in the UK was some time ago, so this is an especially important development,” Louise Longstaff, national veterinary manager at Zoetis UK. “Simparica Trio offers a new licensed route of administration for lungworm treatment in dogs, giving vets another option to what is currently available. It enables them to tailor treatment based on their patient’s needs while still prescribing within the cascade.”
Simparica Trio is a chewable tablet for dogs containing sarolaner, moxidectin and pyrantel. It is a monthly tablet that kills fleas and ticks, treats mites, roundworm and hookworm, prevents and treats lungworm and prevents heartworm disease.
Louise continued: “Zoetis has a strong history of research, innovation and development. This new claim for Simparica Trio ably demonstrates our commitment to delivering a diverse portfolio of animal health medicines, designed to meet the continually evolving needs of veterinarians, giving them best in class products to help support companion animals and their owners.”
For further information, you can contact your Zoetis account manager or call Customer Support on 0345 300 8034.
